Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Avastin vs eylea: which eye drug needs fewer shots?

NCT ID NCT04101877

Disease control Sponsor: Vastra Gotaland Region Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two drugs, Avastin and Eylea, given as eye injections for wet age-related macular degeneration (AMD). The main goal is to see which drug requires fewer injections over two years while still controlling the disease. Researchers will also check vision, eye thickness, and quality of life. About 402 people aged 50 and older with wet AMD are taking part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bevacizumab (Avastin) and aflibercept (Eylea)
What this could lead to
If it works, this could show which drug is more cost-effective and requires fewer injections for wet AMD, improving patient convenience and reducing treatment burden.
What could go wrong
This is a Phase 2 trial, so results are still early. The drugs may work similarly, or one might not be as effective as hoped. Risks include eye infection or inflammation from injections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 402 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2020

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Signed informed consent. ≥50 years, regardless of gender. Diagnosed with the neovascular (wet) form of age-related macular degeneration through diagnosed neovascular vascular membranes with OCT-A and, if necessary, also FA / ICG, according to clinical routine. Distance visual acuity ≥34 (ETDRS) on the current study eye. Exclusion Criteria: Other eye disease in the current study eye that affects visual acuity or the possibility of examining fundus, according to the investigator's assessment. Previously received treatment for the neovascular (wet) form of age-related macular degeneration. Diagnosed with diabetes (all types). Degenerative state of the macula that prevents vision improvement such as central areolar atrophy or other pronounced dry AMD or fibrosis, in the current study eye. Other choroidal neovascularization (CNV) of the type PCV or due to grave myopia i.e. ≥ 6.0 diopters (D) or secondary to other retinal disease, in the current study eye. Unregulated intraocular pressure (IOP) \> 30 mmHg despite pharmacological treatment in the current study eye. Have had a stroke or heart attack ≤6 months ago. Inability to access information (e.g. due to dementia) or inability to conduct examinations (e.g. ETDRS examination), according to the investigator's assessment. Inability to receive oral and written information in Swedish (in need of an interpreter). Included in another intervention study. Fertile woman i.e. a woman who has had menstruation for the past 12 months or has not undergone permanent sterilization (hysterectomy, bilateral salpingectomy or bilateral oophorectomy).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neovascular age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neovascular age-related macular degeneration

Contacts and locations

Locations

  • Vastra Gotaland Region, Sahlgrenska University Hospital, Department of Ophthalmology

    Mölndal, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.